Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P16615

UPID:
AT2A2_HUMAN

ALTERNATIVE NAMES:
Calcium pump 2; Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase

ALTERNATIVE UPACC:
P16615; A6NDN7; B4DF05; P16614; Q86VJ2

BACKGROUND:
The protein Sarcoplasmic/endoplasmic reticulum calcium ATPase 2, also known as SERCA2, is integral to cellular calcium regulation, impacting muscle contraction and metabolic pathways. It is identified by several names, including Calcium pump 2, and is essential for maintaining calcium equilibrium across cellular compartments.

THERAPEUTIC SIGNIFICANCE:
Given SERCA2's critical role in conditions such as Acrokeratosis verruciformis and Darier disease, exploring its mechanisms opens the door to innovative therapeutic approaches. Delving into SERCA2's role could unveil new strategies for managing these genetic skin diseases, potentially revolutionizing treatment paradigms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.